Daewon Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Daewon Pharmaceutical makes prescription and over-the-counter medicines, health supplements, and cosmetics, with products ranging from cold remedies and probiotics to sheet face masks.
It supplies hospitals, clinics, and pharmacies across South Korea, and also exports finished medicines and medical devices to international markets. Listed on KOSPI, South Korea's main stock exchange, the company operates across four segments, pharmaceuticals, cosmetics, health functional foods, and other services, and also manufactures medicines on a contract basis for other Korean pharmaceutical companies.
Summary is AI-generated and may contain errors · figures from DART filings
Its cosmetics subsidiary SD Biotechnologies operates the 'SNP' brand, selling sheet masks and other skincare products in both domestic and overseas markets.
Daewon Pharmaceutical in five facts
What does Daewon Pharmaceutical do?
Daewon Pharmaceutical makes prescription and over-the-counter medicines, health supplements, and cosmetics, with products ranging from cold remedies and probiotics to sheet face masks.
Where is Daewon Pharmaceutical listed and in which sector?
Daewon Pharmaceutical (Korean name: 대원제약) trades under KRX code 003220 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Daewon Pharmaceutical?
Its market capitalisation was US$132M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Daewon Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Daewon Pharmaceutical reported revenue of US$457M, operating profit of US$2.6M and a net loss of US$3M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 1.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meeting (notice)Sep 15
- Cash/in-kind dividend decision
Daewon Pharmaceutical declared a cash dividend of US$0.17 per share.
Dividend · Feb 20 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Daewon Pharmaceutical reported consolidated results for FY2025: revenue of US$417M (+1.2% year on year), operating profit of US$2.36M (−87.8% year on year) and a net loss of US$3.03M (from a profit a year earlier).
Earnings · Feb 3